text: Yo, check it out, I got an aim in sight,
  Stage I small-cell lung cancer, we gonna fight,
  This disease is curable, but we need the right team,
  Timely management, it's a multidisciplinary dream.
  
  In the SEER database, patients we did find,
  To evaluate mortality, we had it on our mind,
  Built a hazard model, proportional subdistribution,
  To assess the chance of cancer-specific perdition.
  
  We crafted a nomogram, based on regression fine,
  Fine and Gray competing risk, it's our design,
  864 patients with stage I SCLC,
  The 5-year mortality incidence, let me break it down, you see.
  
  For SCLC, it's 56.2%, that's the score,
  While other causes of death, 17.3% and no more,
  Our prognostic prediction model, it's got some flair,
  With a c-index of 0.66, we're aware.
  
  And yo, the nomogram, it's calibrated true,
  A reference for clinicians, that's what we do,
  When it comes to stage I SCLC prognosis evaluation,
  Our tool's got the info, no need for hesitation.